ERK‑mediated negative feedback regulation of oncogenic EGFRvIII in glioblastoma cells

Haryuni,Ratna   Dini; Tanaka,Tomohiro; Zhou,Yue; Yokoyama,Satoru; Sakurai,Hiroaki

doi:10.3892/ol.2020.11760

ERK‑mediated negative feedback regulation of oncogenic EGFRvIII in glioblastoma cells

Authors:
- Ratna Dini Haryuni
- Tomohiro Tanaka
- Yue Zhou
- Satoru Yokoyama
- Hiroaki Sakurai
View Affiliations

Affiliations: Department of Cancer Cell Biology, Faculty of Pharmaceutical Sciences, University of Toyama, Toyama 930‑0194, Japan
Published online on: June 19, 2020 https://doi.org/10.3892/ol.2020.11760
Pages: 2477-2482

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Epidermal growth factor receptor variant III (EGFRvIII) is the most common active EGFR mutant in glioblastoma multiforme (GBM). The expression of this mutant often correlates with a poor patient prognosis due to its ability to extend downstream signaling. The EGFR pathway is controlled by a negative feedback mechanism that restricts the extent and length of downstream signaling. To date, the role of negative feedback in the oncogenic EGFRvIII mutant remains undetermined. The present study indicated that activation of the MEK‑ERK pathway led to the phosphorylation of Thr‑402, a conserved negative feedback residue in the juxtamembrane domain corresponding to Thr‑669 of wild‑type EGFR (EGFRwt), which resulted in a rapid reduction in the tyrosine phosphorylation of EGFRvIII in U87MG human glioblastoma and 293 cells. Moreover, despite the incapability of EGFRvIII to bind ligands, EGF was indicated to downregulate the tyrosine phosphorylation of EGFRvIII by activating the EGFRwt‑ERK pathway. These results demonstrated a conserved negative feedback mechanism in the activation of EGFRvIII, which presents a new aspect in functional interactions between EGFRvIII and EGFRwt in glioblastoma cells.

View Figures

View References

1	Huang PH, Xu AM and White FM: Oncogenic EGFR signaling networks in glioma. Sci Signal. 2:re62009. View Article : Google Scholar : PubMed/NCBI
2	Guo G, Gong K, Wohlfeld B, Hatanpaa KJ, Zhao D and Habib AA: Ligand-independent EGFR signaling. Cancer Res. 75:3436–3442. 2015. View Article : Google Scholar : PubMed/NCBI
3	Gan HK, Cvrljevic AN and Johns TG: The epidermal growth factor receptor variant III (EGFRvIII): Where wild things are altered. FEBS J. 280:5350–5370. 2013. View Article : Google Scholar : PubMed/NCBI
4	Gazdar AF: Activating and resistance mutations of EGFR in non-small-cell lung cancer: Role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene. 28 (Suppl 1):S24–S31. 2009. View Article : Google Scholar : PubMed/NCBI
5	Taylor TE, Furnari FB and Cavenee WK: Targeting EGFR for treatment of glioblastoma: Molecular basis to overcome resistance. Curr Cancer Drug Targets. 12:197–209. 2012. View Article : Google Scholar : PubMed/NCBI
6	Padfield E, Hayley P and Kurian KM: Current therapeutic advances targeting EGFR and EGFRvIII in glioblastoma. Front Oncol. 5:52015. View Article : Google Scholar : PubMed/NCBI
7	Bethune G, Bethune D, Ridgway N and Xu Z: Epidermal growth factor receptor (EGFR) in lung cancer: An overview and update. J Thorac Dis. 2:48–51. 2010.PubMed/NCBI
8	An Z, Aksoy O, Zheng T, Fan QW and Weiss WA: Epidermal growth factor receptor and EGFRvIII in glioblastoma: Signaling pathways and targeted therapies. Oncogene. 37:1561–1575. 2018. View Article : Google Scholar : PubMed/NCBI
9	Yang J, Yan J and Liu B: Targeting EGFRvIII for glioblastoma multiforme. Cancer Lett. 403:224–23. 2017. View Article : Google Scholar : PubMed/NCBI
10	Arteaga CL and Engelman JA: ERBB receptors: From oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell. 25:282–303. 2014. View Article : Google Scholar : PubMed/NCBI
11	Gan HK, Kaye AH and Luwor RB: The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci. 16:748–754. 2009. View Article : Google Scholar : PubMed/NCBI
12	Tomas A, Futter CE and Eden ER: EGF receptor trafficking: Consequences for signaling and cancer. Trends Cell Biol. 24:26–34. 2014. View Article : Google Scholar : PubMed/NCBI
13	Chistiakov DA, Chekhonin IV and Chekhonin VP: The EGFR variant III mutant as a target for immunotherapy of glioblastoma multiforme. Eur J Pharmacol. 810:70–82. 2017. View Article : Google Scholar : PubMed/NCBI
14	Keller S and Schmidt MHH: EGFR and EGFRvIII promote angiogenesis and cell invasion in glioblastoma: Combination therapies for an effective treatment. Int J Mol Sci. 18:12952017. View Article : Google Scholar
15	Sato K, Shin MS, Sakimura A, Zhou Y, Tanaka T, Kawanishi M, Kawasaki Y, Yokoyama S, Koizumi K, Saiki I and Sakurai H: Inverse correlation between Thr-669 and constitutive tyrosine phosphorylation in the asymmetric epidermal growth factor receptor dimer conformation. Cancer Sci. 104:1315–1322. 2013. View Article : Google Scholar : PubMed/NCBI
16	Kawasaki Y, Sakimura A, Park CM, Tomaru R, Tanaka T, Ozawa T, Zhou Y, Narita K, Kishi H, Muraguchi A and Sakurai H: Feedback control of ErbB2 via ERK-mediated phosphorylation of a conserved threonine in the juxtamembrane domain. Sci Rep. 6:1–9. 2016. View Article : Google Scholar : PubMed/NCBI
17	Haryuni RD, Watabe S, Yamaguchi A, Fukushi Y, Tanaka T, Kawasaki Y, Zhou Y, Yokoyama S and Sakurai H: Negative feedback regulation of ErbB4 tyrosine kinase activity by ERK-mediated non-canonical phosphorylation. Biochem Biophys Res Commun. 514:456–461. 2019. View Article : Google Scholar : PubMed/NCBI
18	Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, Cavenee WK and Huang HJ: A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA. 91:7727–7731. 1994. View Article : Google Scholar : PubMed/NCBI
19	Nitta Y, Shimizu S, Shishido-Hara Y, Suzuki K, Shiokawa Y and Nagane M: Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo. Cancer Med. 5:486–499. 2016. View Article : Google Scholar : PubMed/NCBI
20	Zhou Y, Yamada N, Tanaka T, Hori T, Yokoyama S, Hayakawa Y, Yano S, Fukuoka J, Koizumi K, Saiki I and Sakurai H: Crucial roles of RSK in cell motility by catalysing serine phosphorylation of EphA2. Nat Commun. 6:76792015. View Article : Google Scholar : PubMed/NCBI
21	Kinoshita E and Kinoshita-Kikuta E: Improved Phos-tag SDS-PAGE under neutral pH conditions for advanced protein phosphorylation profiling. Proteomics. 11:319–323. 2011. View Article : Google Scholar : PubMed/NCBI
22	Lugowska I, Koseła-Paterczyk H, Kozak K and Rutkowski P: Trametinib: A MEK inhibitor for management of metastatic melanoma. Onco Targets Ther. 8:2251–2259. 2015.PubMed/NCBI
23	Najem A, Krayem M, Perdrix A, Kerger J, Awada A, Journe F and Ghanem G: New drug combination strategies in melanoma: Current status and future direction. Anticancer Res. 37:5941–5953. 2017.PubMed/NCBI
24	Li L, Chakraborty S, Yang CR, Hatanpaa KJ, Cipher DJ, Puliyappadamba VT, Rehman A, Jiwani AJ, Mickey B, Madden C, et al: An EGFR wild type-EGFRvIII-HB-EGF feed-forward loop regulates the activation of EGFRvIII. Oncogene. 33:4253–4264. 2014. View Article : Google Scholar : PubMed/NCBI
25	Fan QW, Cheng C, Gustafson WC, Charron E, Zipper P, Wong RA, Chen J, Lau J, Knobbe-Thomsen C, Weller M, et al: EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. Cancer Cell. 24:438–449. 2013. View Article : Google Scholar : PubMed/NCBI
26	Luwor RB, Zhu HJ, Walker F, Vitali AA, Perera RM, Burgess AW, Scott AM and Johns TG: The tumor-specific de2-7 epidermal growth factor receptor (EGFR) promotes cells survival and heterodimerizes with the wild-type EGFR. Oncogene. 23:6095–6104. 2004. View Article : Google Scholar : PubMed/NCBI
27	Kwon SJ, Kwon OS, Kim KT, Go YH, Yu SI, Lee BH, Miyoshi H, Oh E, Cho SJ and Cha HJ: Role of MEK partner-1 in cancer stemness through MEK/ERK pathway in cancerous neural stem cells, expressing EGFRviii. Mol Cancer. 16:1402017. View Article : Google Scholar : PubMed/NCBI
28	Wee P and Wang Z: Epidermal growth factor receptor cell proliferation. Cancers (Basel). 9:522017. View Article : Google Scholar
29	Li L, Puliyappadamba VT, Chakraborty S, Rehman A, Vemireddy V, Saha D, Souza RF, Hatanpaa KJ, Koduru P, Burma S, et al: EGFR wild type antagonizes EGFRvIII-mediated activation of Met in glioblastoma. Oncogene. 34:129–134. 2015. View Article : Google Scholar : PubMed/NCBI
30	Puliyappadamba VT, Chakraborty S, Chauncey SS, Li L, Hatanpaa KJ, Mickey B, Noorani S, Shu HK, Burma S, Boothman DA and Habib AA: Opposing effect of EGFRWT on EGFRvIII-mediated NF-κB activation with RIP1 as a cell death switch. Cell Rep. 4:764–775. 2013. View Article : Google Scholar : PubMed/NCBI